Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Veoneer in connection with its USD 600 million capital raise
Mandate

Vinge advises Veoneer in connection with its USD 600 million capital raise

May 23, 2019 Capital Markets and Public M&A

Veoneer, Inc. (“Veoneer”) has completed a USD 600 million capital raise, consisting of two concurrent offerings of USD 420 million of shares of common stock and USD 180 million aggregate principal amount of convertible senior notes due 2024.

Veoneer is listed on the New York Stock Exchange (NYSE:VNE) and on Nasdaq Stockholm (SSE: VNE SDB). 

Vinge advises Veoneer in relation to Swedish law. Vinge’s team mainly consist of Göran Nyström, Erik Sjöman, Malte Hedlund, Astrid Isberg, Stephanie Stiernstedt, Viktor Bergsten and Anders Sundin Lundberg. Maria Schultzberg advises on tax issues. 
 

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026